Idera Pharmaceuticals Provides Corporate Governance Update
“On behalf of every Idera employee as well as the patients and their families, who are now benefitting from the advancement of our clinical development candidates, I want to thank Youssef for his over two decades of support, commitment and contribution to the mission of Idera,” stated
“It has been the greatest passion of my life to have been a part of this tremendous organization and to now witness the transition from the dream of the science beginning to become the reality for patients suffering from severe unmet needs such as PD-1 refractory melanoma,” stated
About
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, included or incorporated in this press release, including statements regarding the Company's strategy, future operations, collaborations, intellectual property, cash resources, financial position, future revenues, projected costs, prospects, clinical trials, plans, and objectives of management, are forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," "continue," "will," and "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Idera cannot guarantee that it will actually achieve the plans, intentions or expectations disclosed in its forward-looking statements and you should not place undue reliance on the Company's forward-looking statements. There are a number of important factors that could cause Idera's actual results to differ materially from those indicated or implied by its forward-looking statements. Factors that may cause such a difference include: whether the Company’s cash resources will be sufficient to fund the Company’s continuing operations for the period anticipated; whether interim results from a clinical trial will be predictive of the final results of the trial; whether results obtained in preclinical studies and clinical trials will be indicative of the results that will be generated in future clinical trials, including in clinical trials in different disease indications; whether products based on Idera's technology will advance into or through the clinical trial process when anticipated or at all or warrant submission for regulatory approval; whether such products will receive approval from the
Investor and Media Contact
VP,
617-679-5515 (office)
484‐639‐7235 (mobile)
rdoody@iderapharma.com
Source: Idera Pharmaceuticals, Inc.